71 related articles for article (PubMed ID: 15907712)
1. A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.
Winquist E; Moore MJ; Chi KN; Ernst DS; Hirte H; North S; Powers J; Walsh W; Boucher T; Patton R; Seymour L
Urol Oncol; 2005; 23(3):143-9. PubMed ID: 15907712
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group.
Kitamura H; Taguchi K; Kunishima Y; Yanase M; Takahashi A; Shigyo M; Tanaka T; Mutoh M; Fukuta F; Masumori N; Tsukamoto T
Cancer Sci; 2011 Jun; 102(6):1171-5. PubMed ID: 21323791
[TBL] [Abstract][Full Text] [Related]
3. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study.
Ko YJ; Canil CM; Mukherjee SD; Winquist E; Elser C; Eisen A; Reaume MN; Zhang L; Sridhar SS
Lancet Oncol; 2013 Jul; 14(8):769-76. PubMed ID: 23706985
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
Castaneda C; Meadows KL; Truax R; Morse MA; Kaufmann SH; Petros WP; Zhu Y; Statkevich P; Cutler DL; Hurwitz HI
Cancer Chemother Pharmacol; 2011 Feb; 67(2):455-63. PubMed ID: 20972873
[TBL] [Abstract][Full Text] [Related]
5. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Kim ES; Kies MS; Fossella FV; Glisson BS; Zaknoen S; Statkevich P; Munden RF; Summey C; Pisters KM; Papadimitrakopoulou V; Tighiouart M; Rogatko A; Khuri FR
Cancer; 2005 Aug; 104(3):561-9. PubMed ID: 16028213
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of paclitaxel and cisplatin for advanced urothelial cancer.
Burch PA; Richardson RL; Cha SS; Sargent DJ; Pitot HC; Kaur JS; Camoriano JK
J Urol; 2000 Nov; 164(5):1538-42. PubMed ID: 11025699
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma.
Rosenberg JE; von der Maase H; Seigne JD; Mardiak J; Vaughn DJ; Moore M; Sahasrabudhe D; Palmer PA; Perez-Ruixo JJ; Small EJ
Cancer; 2005 May; 103(10):2035-41. PubMed ID: 15812833
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Borthakur G; Kantarjian H; Daley G; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Faderl S; Sugrue M; Cortes J
Cancer; 2006 Jan; 106(2):346-52. PubMed ID: 16342165
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
Hanrahan EO; Kies MS; Glisson BS; Khuri FR; Feng L; Tran HT; Ginsberg LE; Truong MT; Hong WK; Kim ES
Am J Clin Oncol; 2009 Jun; 32(3):274-9. PubMed ID: 19433965
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Ready NE; Lipton A; Zhu Y; Statkevich P; Frank E; Curtis D; Bukowski RM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):576-83. PubMed ID: 17255280
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Kyriakakis Z; Dimopoulos MA; Kostakopoulos A; Karayiannis A; Sofras F; Zervas A; Giannopoulos A; Dimopoulos C
J Urol; 1997 Aug; 158(2):408-11. PubMed ID: 9224313
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy in the management of pT3N0M0 transitional cell carcinoma of the upper urinary tract.
Lee SE; Byun SS; Park YH; Chang IH; Kim YJ; Hong SK
Urol Int; 2006; 77(1):22-6. PubMed ID: 16825811
[TBL] [Abstract][Full Text] [Related]
14. Pathologic features of bladder tumors after nephroureterectomy or segmental ureterectomy for upper urinary tract transitional cell carcinoma.
Raman JD; Sosa RE; Vaughan ED; Scherr DS
Urology; 2007 Feb; 69(2):251-4. PubMed ID: 17320658
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.
Sweeney CJ; Roth BJ; Kabbinavar FF; Vaughn DJ; Arning M; Curiel RE; Obasaju CK; Wang Y; Nicol SJ; Kaufman DS
J Clin Oncol; 2006 Jul; 24(21):3451-7. PubMed ID: 16849761
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.
Kieran MW; Packer RJ; Onar A; Blaney SM; Phillips P; Pollack IF; Geyer JR; Gururangan S; Banerjee A; Goldman S; Turner CD; Belasco JB; Broniscer A; Zhu Y; Frank E; Kirschmeier P; Statkevich P; Yver A; Boyett JM; Kun LE
J Clin Oncol; 2007 Jul; 25(21):3137-43. PubMed ID: 17634493
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter.
Papamichael D; Gallagher CJ; Oliver RT; Johnson PW; Waxman J
Br J Cancer; 1997; 75(4):606-7. PubMed ID: 9052419
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant methotrexate, vinblastine and cisplatin chemotherapy for invasive transitional cell carcinoma: Taiwan experience.
Wei CH; Hsieh RK; Chiou TJ; Chen KK; Chang LS; Chen PM
J Urol; 1996 Jan; 155(1):118-21. PubMed ID: 7490806
[TBL] [Abstract][Full Text] [Related]
20. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
